Skin fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) in the dermis, can lead to hypertrophic scars and impaired mobility. The ErbB family of receptor tyrosine kinases, including ErbB1 and ErbB2, plays a crucial role in organ fibrosis, but their specific impact on skin fibrosis is less understood. This study investigated the role of ErbB1 and ErbB2 in skin fibrosis and the therapeutic potential of lapatinib, a dual ErbB1 and ErbB2 tyrosine kinase inhibitor. Using qPCR, cell culture assays, Western blotting, and in vivo models, we found significant upregulation of ErbB1 and ErbB2 in keloid tissues and fibroblasts. Lapatinib treatment resulted in a dose-dependent decrease in ErbB1 and ErbB2 expression, which suppressed the expression of fibroblast activation markers. Our findings suggest that lapatinib may be a promising therapeutic agent for skin fibrosis by targeting ErbB1/ErbB2 and modulating the TGF-β1/Smad2/3/Erk/Akt signalling pathways. These results warrant further clinical investigation into lapatinib for treating skin fibrosis and related conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41598-025-92687-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of 70% and 100% concentration of trichloroacetic acid peeling efficacy with chemical reconstruction of skin scars technique in atrophic acne scar treatment.
Arch Dermatol Res
March 2025
Dermatology Department, Gaziantep University Hospital, Gaziantep, Turkey.
Introduction: The CROSS (Chemical Reconstruction of Skin Scars) technique employs high concentrations of trichloroacetic acid (TCA). This study aimed to compare the efficacy, safety, and tolerability of the CROSS technique using 70% and 100% TCA.
Methods: A total of 40 patients were randomly assigned to two equal groups of 20: the first group received 70% TCA, while the second group was treated with 100% TCA.
Mesoderm/mesenchyme homeobox l as a potential target that orchestrates hepatic stellate cell activation.
Adv Clin Exp Med
March 2025
Department of Internal Medicine, Hebei Medical University, Shijiazhuang, China.
Background: Hepatic stellate cell (HSC) activation is a critical factor in the development of liver fibrosis. Recent research indicates that mesoderm/mesenchyme homeobox 1 (Meox1) contributes to fibrosis in organs like the skin and heart.
Objectives: To investigate the potential impact of Meox1 on HSC activation and provide an available target for hepatic fibrosis research.
Gynecological issues in children and adolescents seen at rare-disease referral centers: an observational retrospective cohort study.
Orphanet J Rare Dis
March 2025
Pediatric Endocrinology, Diabetology, Gynecology Department, Necker-Enfants Malades University Hospital, AP-HP Centre, 75015, Paris, France.
Background: The current development of gynecology services for children and adolescents seeks to meet needs both in the overall population and in patients with rare diseases. In France, the referral center for rare gynecological diseases specializes in four major types of conditions, namely, uterovaginal malformations, hereditary hemorrhagic diseases, rare benign breast diseases, and gynecological repercussions of rare chronic diseases.
Objective: To describe consecutive patients who had a first visit in 2018-2023 at the referral center for rare gynecological diseases at the Necker Pediatric University Hospital in Paris, France, and who were diagnosed with a condition in any of the four categories listed above.
Fractional carbon dioxide laser treatment of hypertrophic scar clinical and histopathological evaluation.
Lasers Med Sci
March 2025
National Institute of Laser Enhanced Science, Egypt Cairo University, Al Giza, Egypt.
Hypertrophic scar could be associated with several complications that interfere with patient daily activities, physical and psychological health and impact patient quality of life. Several therapeutics and maneuvers are used for treatment of hypertrophic scar with variable success and side effects. We aim to evaluate safety and efficacy of fractional carbon dioxide laser on treatment of hypertrophic scar both clinically and histopathologically.
View Article and Find Full Text PDFLapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway.
Sci Rep
March 2025
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, China.
Skin fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) in the dermis, can lead to hypertrophic scars and impaired mobility. The ErbB family of receptor tyrosine kinases, including ErbB1 and ErbB2, plays a crucial role in organ fibrosis, but their specific impact on skin fibrosis is less understood. This study investigated the role of ErbB1 and ErbB2 in skin fibrosis and the therapeutic potential of lapatinib, a dual ErbB1 and ErbB2 tyrosine kinase inhibitor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!